Felsenstein Medical Research Center

Breast Cancer Research

Oncology and Hematology

Equal contribution. Pharmacological induction of cell surface GRP78 contributes to apoptosis in triple negative breast cancer cells. Oncotarget, 2014;5(22):11452-63. doi: 10.18632/oncotarget.2576.

A. Raiter, R. Yerushalmi, B. Hardy.

למחקר

Equal contribution. Cell surface GRP78: A potential marker of good prognosis and response to chemotherapy in breast cancer. Oncology Letters 2015; 10(4):2149-2155. doi: 10.3892/ol.2015.3579.

R. Yerushalmi, A. Raiter, K. Nalbandyan, B. Hardy.

למחקר

GRP78 expression in peripheral blood mononuclear cells is a new predictive marker for the benefit of taxanes in breast cancer neoadjuvant treatment. BMC Cancer (2020) 20:333. doi.org/10.1186/s12885-020-06835-z.

A. Raiter, J. Lipovetsky, I. Lubin, R. Yerushalmi

למחקר
Chemotherapy controls metastasis through GRP78 and its transcription factor CREB3L1. Frontiers in Oncology (2020) 10:1500. doi: 10.3389/fonc.2020.01500

A. Raiter, J. Lipovetski, L. Hyman, S. Mugami, T. Ben-Zur, and R. Yerushalmi

למחקר

A novel role for an old target: CD45 for breast cancer immunotherapy, OncoImmunology (2021) 10:1, DOI: 10.1080/2162402X.2021.1929725

A. Raiter, O. Zlotnik, J. Lipovetsky, S. Mugami, S. Dar, I. Lubin, E. Sharon, C. J. Cohen, R. Yerushalmi.

למחקר
Downregulation of CD45 Signaling in COVID-19 Patients is reversed by C24D, a novel CD45 targeting peptide. Frontiers in Medicine, 2021

Alon, Y. Paitan, E. Robinson, N. Ganor, J. Lipovetsky, R. Yerushalmi, C. J Cohen, A. Raiter.

למחקר